from this treatment in terms of overall survival. The goal of our laboratory is to develop better therapies to enhance a patient's own immune response against his or her tumor; these therapies may be useful alone or as an adjuvant therapy in combination with chemotherapy or radiation. A large part of our effort is being devoted to the examination of mild, long-duration (fever-like) whole-body hyperthermia (WBH) as a possible means to help stimulate the immune system. [1] [2] [3] When clinical hyperthermia was first conceived for use in cancer treatment, it was envisioned as a type of thermal radiation therapy whereby a heat treatment sufficient to sterilize or directly kill cancer cells would selectively be delivered to the tumor. It has been noted in the past few years, however, that the tumor temperatures achieved during these local treatments were well below those known to be cytotoxic. [4] [5] [6] Whole-body hyperthermia protocols have been developed that have employed temperatures as high as 42C given for durations ranging from 15 min. to were very similar with regard to the tumor growth delay (Fig. 4) 
